Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
by Christina Black | May 9, 2018...
PD-L1 driven excluded phenotype in melanoma
by Christina Black | Apr 14, 2018
Comprehensive Immune and Mutational Profile of Melanoma
by OmniSeq Staff | Jan 25, 2018
CTLA-4 Overexpression Does Not Confer Response to Ipilimumab in Melanoma
by OmniSeq Staff | Jan 13, 2018
Follow Us on Twitter
Finding the right drug or the right trial...for every #cancer patient. #immunotherapy Pronounced OmniSeek
Thank you to the many OmniSeq partners and followers who have been a part of our community! We appreciate your support and are looking forward to continuing the conversation around cancer diagnostics now that OmniSeq is part of Labcorp. Join us here: http://spr.ly/60113sQzZ
OmniSeq® is now part of Labcorp. Be sure to follow Labcorp to stay up-to-date on the latest #oncology updates. We look forward to providing timely and relevant information about how we are driving precision cancer care forward: https://bit.ly/3BdrZUu
This December, Dr. Sarabjot Pabla joins the speaker lineup for the TIGIT Axis Therapies Digital Summit. His presentation will focus on TIGIT RNA expressions and their impact in precision oncology medicines. Register for the virtual event today: https://bit.ly/3NAKg3S
LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
June 3-7 | Chicago, I Join us @ASCO 2022. LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
Sunday, June 5, 8-11:00 AM CDT